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Proof of Concept
Hemodynamic Response to Long-Term Partial
Ventricular Support With the Synergy Pocket Micro-Pump
Bart Meyns, MD, PHD,* Stefan Klotz, MD, PHD,† Andre Simon, MD,‡ Walter Droogne, MD,*
Filip Rega, MD,* Bartley Griffith, MD,§ Robert Dowling, MD, Mark J. Zucker, MD,¶
Daniel Burkhoff, MD, PHD#**
Leuven, Belgium; Münster and Hannover, Germany; Baltimore, Maryland; Louisville, Kentucky;
Newark and Saddle Brook, New Jersey; and New York, New York
Objectives The purpose of this study was to test the hemodynamic effects of partial ventricular support in patients with ad-
vanced heart failure.
Background The use of current left ventricular assist devices (VADs) that provide full circulatory support is restricted to criti-
cally ill patients because of associated risks. Smaller, less-invasive devices could expand VAD use to a larger
pool of less-sick patients but would pump less blood, providing only partial support.
Methods The Synergy Pocket Micro-pump device (CircuLite, Inc., Saddle Brook, New Jersey) pumps 3.0 l/min, is im-
planted (off pump) via a mini-thoracotomy, and is positioned in a right subclavicular subcutaneous pocket (like a
pacemaker). The inflow cannula inserts into the left atrium; the outflow graft connects to the right subclavian
artery.
Results A total of 17 patients (14 men), age 53  9 years with ejection fraction 21  6%, mean arterial pressure 73 
7 mm Hg, pulmonary capillary wedge pressure 29  6 mm Hg, and cardiac index 1.9  0.4 l/min/m2 received
an implant. Duration of support ranged from 6 to 213 (median 81) days. In addition to demonstration of signifi-
cant acute hemodynamic improvements in the first day of support, 9 patients underwent follow-up right heart
catheterization at 10.6  6 weeks. These patients showed significant increases in arterial pressure (67  8 mm
Hg vs. 80  9 mm Hg, p  0.01) and cardiac index (2.0  0.4 l/min/m2 vs. 2.8  0.6 l/min/m2, p  0.01)
with large reductions in pulmonary capillary wedge pressure (30  5 mm Hg vs. 18  5 mm Hg, p  0.001).
Conclusions Partial support appears to interrupt the progressive hemodynamic deterioration typical of late-stage heart fail-
ure. If proven safe and durable, this device could be used in a relatively large population of patients with severe
heart failure who are not sick enough to justify use of currently available full support VADs. (Safety and Perfor-
mance Evaluation of CircuLite Synergy; NCT00878527). (J Am Coll Cardiol 2009;54:79–86) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.023r
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fommonly used left ventricular assist devices (LVADs) are
esigned to provide full hemodynamic support for the
nd-stage failing heart (1). With flow rate capacities ranging
rom 5 to 10 l/min, these LVADs also provide profound left
entricular pressure and volume unloading, which, during
rolonged use, results in structural and functional reverse
rom the *University of Leuven, Leuven, Belgium; †University of Münster, Münster,
ermany; ‡Hannover Medical School, Hannover, Germany; §University of Mary-
and, Baltimore, Maryland; Univeristy of Louisville, Louisville, Kentucky; ¶Newark
eth Israel Medical Center, Newark, New Jersey; #CircuLite, Inc., Saddle Brook,
ew Jersey; and **Columbia University, New York, New York. This study was
upported by CircuLite, Inc., Saddle Brook, New Jersey. Dr. Burkhoff is an employee
f CircuLite, Inc. Drs. Meyns, Griffith, Dowling, and Zucker are consultants to
ircuLite, Inc.c
Manuscript received March 2, 2009; revised manuscript received April 3, 2009,
ccepted April 6, 2009.emodeling (1,2). However, even modern LVADs are
elatively large, require a major surgical procedure with a
ternotomy, and require extracorporeal circulation for their
nsertion. Such devices are associated with significant rates
f morbidity and mortality.
See page 87
We have recently introduced a smaller device that pumps
.5 to 3.0 l/min (Synergy Pocket Micro-pump, CircuLite,
nc., Saddle Brook, New Jersey) and suggested that such a
evice could be used to provide hemodynamic benefit to
atients with medically refractory, severe symptomatic heart
ailure but who do not yet meet current hemodynamic and
linical criteria to justify the risks associated with implan-
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support LVAD (3,4). Patient se-
lection and expectations con-
cerning hemodynamic improve-
ments initially were guided by
results of previous short-term
partial support devices (5–8) and a
computer simulation that predi-
cated hemodynamic responses in
various degrees of heart failure
9). We then embarked on a feasibility study to test, for the
rst time, the hypothesis that chronic partial ventricular
upport can interrupt the progressive hemodynamic deteri-
ration typical of end-stage heart failure and result in
enefits beyond what is achieved in the acute setting.
ethods
his was a prospective, treatment-only feasibility study.
atients were eligible for inclusion if they were between 18
nd 70 years of age; had New York Heart Association
unctional class IIIb or IV symptoms despite appropriate
reatment with diuretics, angiotensin-converting enzyme
nhibitor or angiotensin receptor blockade, and beta-blocker
unless intolerant); or were listed for heart transplantation
nd were ambulatory, but whose condition was becoming
linically unstable (e.g., frequent hospitalizations for heart
ailure or increasingly symptomatic). The main exclusion
riteria included the requirement for continuous inotropic
upport; isolated right heart failure; previous surgery in the
ight chest that could impede access to the left atrium from
aterson’s groove for implantation of the inflow cannula;
2 aortic regurgitation; mechanical mitral valve prosthe-
is; left atrial thrombus on echocardiogram; cerebrovascular
ccident within the previous 6 months; creatinine 2.5
g/dl; aspartate aminotransferase, alanine aminotransfer-
se, or total bilirubin2 times the upper limit of normal; or
ontraindication to anticoagulation.
After informed consent, patients underwent a right heart
atheterization, a cardiopulmonary stress test, and thoracic
omputed tomography (CT) scan with contrast (to exclude
ight subclavian artery stenosis), serum b-type natriuretic
eptide level and routine blood chemistries and hematologic
valuation. An INTERMACS (Interagency Registry for
echanically Assisted Circulatory Support) heart failure se-
erity score was also assigned (10). In brief, INTERMACS
lass 1 patients are patients with critical cardiogenic shock, class
patients are progressively declining on inotropic support, class
patients are stable but inotrope dependent, and class 4
atients exhibit recurrent decompensations requiring repeated
ospitalizations.
After baseline information was obtained, the results were
resented by the site principal investigator to a clinical
eview committee, which was composed of 2 heart failure
urgeons (B.G. and R.D.) and 1 heart failure cardiologist
Abbreviations
and Acronyms
CT  computed
tomography
INR  international
normalized ratio
LVAD  left ventricular
assist deviceM.J.Z.). The purpose of the clinical review committee was po ensure that the baseline data were complete, that the
atient was not “too sick” to potentially derive clinical
enefit from 3.0 l/min pump flow, and that there were no
nforeseen contraindications for implantation.
urgical implantation procedure. A 4-cm subclavicular
ncision was made to isolate the right subclavian artery. A
mall subcutaneous pocket was formed for the pump ante-
ior to the right pectoralis major muscle, similar to a
acemaker pocket. An incision was then made in the right
ourth intercostal space to gain access through Waterson’s
rove to the left atrium. A nitinol reinforced silicone inflow
annula with a titanium tip and Dacron cuff was inserted on
trocar over a guidewire into the left atrium between the
nsertions of the right upper and lower pulmonary veins and
ecured with 2 purse string sutures. The proximal end of
nflow cannula was tunneled through the second intercostal
pace to exit the thorax in the area of the subcutaneous
ocket. An 8-mm polytetrafluoroethylene outflow graft was
nastomosed to the subclavian artery. The driveline of the
ump was then tunneled to exit the body over the right
pper quadrant of the abdomen. After completing the initial
mplant, the pump was turned on and speed was generally
ncreased slowly from 20,000 to 26,000 rpm while cardiac
utput, pulmonary artery pressure, and arterial pressure
ere measured. The final speed was generally set at the level
t which no further increase in cardiac output was observed,
hich generally was either 22,000 or 24,000 rpm, resulting
n a pump flow of 3.0 l/min. After confirming proper
ump functioning, the surgical wounds were closed.
After surgery, the patients were taken to the intensive
are unit and, in clinically appropriate stages, were extu-
ated, weaned from any inotropic support, brought to the
egular medical ward, and ambulated, and physical therapy
as initiated. The surgical procedures generally took from
0 to 120 min. Patients were extubated within 12 h of
ompleting surgery (with some extubated in the operating
oom). Stays in the intensive care unit generally ranged from
to 4 days. Patients and family members were trained in the
se of the controller, battery charger, and how to change
atteries. After appropriate training, patients were dis-
harged home. Hospital stays lasted a median of 17 days.
atients were anticoagulated with aspirin (100 mg/day) and
arfarin. The initial international normalized ratio (INR)
arget was 2.0 to 2.5 based on the pre-clinical animal
xperience in which pumps were implanted for 90 days
ithout any anticoagulation. As will be detailed herein,
ump thrombosis did become an issue and, in addition to a
evice modification, the target range for INR was increased
o 2.5 to 3.0.
The protocol called for patients to return for a right heart
atheterization between 1 and 3 months after implantation
f the device. Some patients underwent transplantation
efore this point, and in other cases the patients or physi-
ians were reluctant to undergo this invasive test. At the
resent time, such data are available from 9 of the patients.
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June 30, 2009:79–86 Long-Term Benefits of Partial Ventricular Supporttatistics. Descriptive statistics are used to summarize data
ith results expressed as means with SDs, unless otherwise
oted. Comparison of data between time points was made
ith paired t tests.
esults
atient characteristics. Baseline demographics and treat-
ents of the 17 patients treated are summarized in Table 1.
urgeries were performed in Leuven, Belgium (n 10), and
ünster (n 3) and Hannover (n 4), Germany. Patients
ere between 34 and 63 years of age, were mainly men, and
eart failure was mainly on the basis of ischemic cardio-
yopathy. Most patients were INTERMACS class 4, but
here was 1 class 2 and 1 class 3 patient. These latter 2
atients (both deviations from the protocol) were admitted
o the protocol early in the study after several, initial
uccessful outcomes (see the “Overall clinical outcomes and
dverse events” section for more details). Almost one-half of
he patients had atrial fibrillation. Sixty percent of patients
ad an internal cardiac defibrillator, and most patients were
n optimal medical therapy with diuretics, angiotensin-
onverting enzyme inhibitor or angiotensin receptor block-
de, beta-blocker, and aldosterone inhibitor.
aseline Demographics of the 17 Study Patients
Table 1 Baseline Demographics of the 17 Study Patients
Mean SD Minimum Maximum
Age (yrs) 52.6 8.7 34 63
Body surface area (m2) 2.0 0.2 1.7 2.3
Body mass index (kg/m2) 26.0 3.5 21.2 34.0
n %
Sex
Male 14 82.4
Female 3 17.6
Congestive heart failure etiology
Ischemic cardiomyopathy 14 82.4
Dilated cardiomyopathy 3 17.6
Interagency Registry for
Mechanically Assisted
Circulatory Support
Class 2 1 5.9
Class 3 1 5.9
Class 4 15 88.2
Diabetes mellitus 4 24
Atrial fibrillation 7 41
Treatments
Implantable cardioverter-
defibrillator
10 59
Diuretic 17 100
Beta-blocker 12 71
Angiotensin-converting
enzyme inhibitor
11 65
Angiotensin receptor
blockade
3 18
Aldactone 13 76
Aspirin 8 47
Warfarin 3 18
Statin drug 8 47dBaseline hemodynamic and functional parameters are
ummarized in Table 2. As seen, patients were significantly
ompromised, with increased heart rates, low blood pres-
ures, increased central venous, pulmonary and capillary
edge pressures, low cardiac indexes, increased pulmonary
ascular resistances, dilated poorly contracting left ventricles
frequently with significant mitral regurgitation), and very
ompromised exercise tolerances. Twelve of the patients had
o detectible aortic regurgitation, and 5 patients had 1
ortic regurgitation. Brain natriuretic peptide levels were
ignificantly increased. Renal and hepatic functions were
enerally well preserved.
Figure 1 shows an X-ray image and a 3-dimensional
econstructed CT scan after a Synergy Pocket Micro-pump
mplant in a patient with previous cardiac surgery and an
mplantable cardioverter-defibrillator. The CT scan shows
he inflow cannula exiting the left atrium in a direct lateral
aseline Hemodynamic andunct onal Parameters of the 17 Study Patients
Table 2 Baseline Hemodynamic andFunctional Parameters of the 17 Study Patients
Mean SD Minimum Maximum
Hemodynamics
Heart rate (beats/min) 79.4 17.4 50 112
Systolic blood pressure
(mm Hg)
96.2 13.2 80 122
Diastolic blood pressure
(mm Hg)
63.0 7.1 52 80
Mean arterial pressure
(mm Hg)
73.2 7.4 61 91
Central venous pressure
(mm Hg)
13.4 3.9 7 22
Systolic PAP (mm Hg) 57.4 14.3 36 90
Diastolic PAP (mm Hg) 28.8 7.1 20 45
Mean PAP (mm Hg) 38.9 7.5 28 56
PCWP (mm Hg) 29.4 6.0 21 43
Cardiac output (l/min) 3.8 0.8 2.5 5
Cardiac index (l/min/m2) 1.9 0.4 1.3 2.6
Systemic vascular resistance
(Wood units)
14.8 2.8 11.1 20.4
Pulmonary vascular resistance
(Wood units)
2.5 1.1 1.3 5.2
Echocardiography
Ejection fraction (%) 20.9 6.2 10.0 32.0
Left ventricular end-diastolic
and -systolic dimension (cm)
6.9 0.9 5.4 9.2
Mitral regurgitation (grade) 1.6 0.7 0.0 3.0
Aortic regurgitation (grade) 0.3 0.5 0.0 1.0
Peak VO2 (ml/kg/min) 9.7 2.0 6.3 12.9
Laboratory findings
Brain natriuretic peptide
(pg/ml)
7,251 5,758 1,011 21,359
Creatinine (mg/dl) 1.4 0.5 0.7 2.6
Total bilirubin (mg/dl) 1.0 0.6 0.5 2.8
Aspartate aminotransferase
(U/l)
28 14 14 62
Alanine aminotransferase
(U/l)
39 26 12 128
AP  pulmonary arterial pressure; PCWP  pulmonary capillary wedge pressure; VO2  rate of
xygen uptake.Inotrope(s) 2 12 irection, taking a serpentine course anteriorly and superi-
o
r
t
i
P
s
w
i
w
s
1
a
h
A
s
m
m
b
8
p
2
3
c
1
a
3
i
p
C
p
(
i
s
t
0
a
r
t
d
p
d
5
o
m
c
t
a
c
r
O
82 Meyns et al. JACC Vol. 54, No. 1, 2009
Long-Term Benefits of Partial Ventricular Support June 30, 2009:79–86rly to exit the thorax in the second intercostal space to
each the pump. The outflow graft is shown anastomosed to
he subclavian artery. The driveline is also seen coursing
nferiorly on the exterior of the thoracic cage.
lasma-free hemoglobin. Plasma-free hemoglobin mea-
urements that were taken during the first month of support
ere obtained from 14 of the patients. Results, summarized
n Figure 2, show that with the exception of 1 patient in
hich plasma-free hemoglobin reached 44 mg/dl, the mea-
urements were typically undetectable and rarely exceeded
0 mg/dl. Measurements made at longer time points (avail-
ble in some of the patients) showed no late events of
emolysis.
cute hemodynamic effects. Pump speed the day after
urgery ranged between 20,000 and 25,000 rpm and esti-
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Figure 2 Plasma-Free Hemoglobin Over Time
Plasma-free hemoglobin values obtained during the first 4 weeks of support
show that there is minimal hemolysis during use of the Synergy Micro-pump.
Figure 1 Patient With Synergy Pump
Chest X-ray (left) and corresponding 3-dimensional reconstruction (right) of a patirated pump flow was 3.0  0.4 l/min. Hemodynamics
easured the day after surgery showed that compared with
aseline results, mean blood pressure was maintained (71 
mm Hg vs. 71  9 mm Hg, p  0.79) and that diastolic
ulmonary artery pressure decreased from 27 3 mm Hg to
1  7 mm Hg (p  0.01), cardiac output increased from
.8  0.8 l/min to 6.3  1.7 l/min (p  0.0001), and
ardiac index increased from 2.0  0.4 l/min/m2 to 3.3 
.0 l/min/m2 (p  0.0001). When patients were grouped
ccording to minimal (0 or 1, n  6) or moderate (2 or
, n  11) mitral regurgitation, no significant differences
n hemodynamic effects were identified (p values by un-
aired t test 0.34 for all hemodynamic variables tested).
hronic effects. Nine of the patients returned for the
rotocol-specified right heart catheterization 4 to 19
mean 10) weeks after implant. Results are summarized
n Figure 3. As reviewed previously for the entire cohort,
ignificant hemodynamic improvements were realized within
he first 24 h of support, with estimated pump flows of 2.8 
.4 l/min. In the chronic setting, with estimated pump flow
lso averaging 2.8  0.4 l/min, increases in blood pressure,
eductions in pulmonary artery systolic pressure, and main-
enance of improved cardiac indexes and pulmonary artery
iastolic pressures are observed. Pulmonary capillary wedge
ressures (not generally available at the 24-h time point)
ecreased from a baseline of 29.7  5.0 mm Hg to 17.8 
.3 mm Hg (p  0.001). Serum creatinine was maintained
r decreased over this follow-up period, averaging 1.5 0.6
g/dl at baseline to 1.3  0.6 mg/dl at follow-up. A
omparison of medication use before implant and at the
ime of the follow-up showed a slightly greater use of
ngiotensin-converting enzyme inhibitors, angiotensin re-
eptor blockers, and aldosterone inhibitors, with a slight
eduction in diuretic use in the follow-up period.
verall clinical outcomes and adverse events. The du-
h a Synergy Micro-pump.ent witation of support has ranged from 6 to 213 (median 81)
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June 30, 2009:79–86 Long-Term Benefits of Partial Ventricular Supportays. At the time of this writing, 4 of the 17 patients are
urrently on continued support and doing well (at post-
perative days 176, 121, 46, and 29). Nine patients have
ndergone transplantation successfully. Among these are
he INTERMACS class 2 and 3 patients; these patients
voided the need for implantation of a full support
VAD, although they remained hospitalized for the
uration of support until heart transplant.
Thirteen of the 17 patients were discharged to home with
mean time to discharge of 18 (range 12 to 26) days. At one
ite (Hannover), the patients were initially discharged to a
ardiac rehabilitation center, which is standard post-cardiac
urgical care; all of these patients eventually went home. By
eport, all of these patients markedly increased their level of
ctivity. Follow-up B-type natriuretic protein values, avail-
ble from 9 of these ambulatory patients between 1 and 3
onths after device implant, showed a mean (SEE)
eduction of 4,475  1,389 pg/ml (from 6,856  1,952
g/ml to 2,381  675 pg/ml, p  0.02). Formal stress
esting was performed in only 5 of the ambulatory patients
t both baseline and between 1 and 3 months after dis-
harge; peak VO2 increased by a mean value (SD) of 4.5
2.0 ml/kg/min (from 9.6  2.0 ml/kg/min to 14.1  1.6
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Figure 3 Hemodynamics Over Time
Hemodynamic parameters from 9 patients (with mean and SD) who returned for fo
The p values are for comparison between baseline and chronic follow-up. Red linel/kg/min, p  0.01). rOne patient required conversion to a biventricular sup-
ort device on post-operative day 7; in this case, the Synergy
ump was removed, and the patient was implanted with an
xcor (Berlin Heart, Berlin, Germany) full biventricular
upport device.
There were 3 deaths. One was the consequence of sepsis
rom an unrecognized renal abscess (post-operative day 7).
he second patient, who was clinically stable and doing very
ell at home, returned to the hospital for the protocol-
pecified outpatient right heart catheterization (post-
perative day 70). The patient developed a fever that
vening but did not notify the investigator. He was brought
o the hospital urgently 2 days later with hypotension,
ltered mental status, and renal failure; blood cultures were
ositive for Staphylococcus aureus. Despite aggressive resus-
itation, intubation, and antibiotic therapy, the patient
uccumbed to multiorgan failure. The third death occurred
n a patient who was successfully supported for 167 days
ho self-discontinued his anticoagulation; after 6 days
ithout anticoagulants, the patient returned to the hospital,
t which time extensive pump thrombosis and an INR of
.0 were noted. The patient was stable, and an elective
rocedure to replace the pump was performed, which
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Long-Term Benefits of Partial Ventricular Support June 30, 2009:79–86In addition to the aforementioned deaths and conversion
o biventricular support, notable major adverse events ob-
erved included 3 pocket hematomas in the perioperative
eriod that required surgical drainage (although no specific
leeding was noted), a large serous pleural effusion that
equired thoracocentesis, 1 pump pocket infection that
leared with the administration of antibiotics, 1 gastroin-
estinal bleed that necessitated the discontinuation of war-
arin, and 1 transient renal failure (in the patient who was
NTERMACS class 2 at baseline).
In addition, 8 of the first 12 patients required pump
xchanges because of thrombus formation and pump stop-
age. To address this, the study was temporarily halted, the
imensions of a washout channel within the pump rotor
ere increased to enhance washing within the rotor, and the
Figure 4 Cannula Tips at Time of Heart Transplant
Pictures of the tip of the inflow cannula taken from the left atrium of 3 patients ob
Figure 5 Rotor Images at Time of Explant
Pictures of the rotor after the specified number of days of support showing that tharget range for INR was increased from 2.0–2.5 to 2.5–3.0.
ine of the modified rotors have been used with no episodes
f thrombosis during long-term use (discussed in the
Device explants at transplant” section). Bench testing
howed that the pressure-flow characteristics of the pump
as not changed detectably by this minor design change,
hich justifies pooling of the previous hemodynamic data.
evice exchanges were performed within 24 h of pump
toppage in a procedure that lasted 30 to 60 min.
evice explants at transplant. Examples of inflow cannula
ip appearances at the time of heart transplantation (after
7, 51, and 213 days of support) are shown in Figure 4.
hese examples, typical of all explants, show well-healed
issue covering the Dacron cuff and no tissue on the
itanium tip. Examples of rotors (with the increased dimen-
at the time of heart transplant. The cannula is well healed.
is free of thrombus and remnants of cellular debris.tainede rotor
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June 30, 2009:79–86 Long-Term Benefits of Partial Ventricular Supportions of the washout channel) and the pivot bearings on
hich they rotate, explanted after 117 and 108 days of use,
re shown in Figure 5. The rotors and bearings are com-
letely free of thrombus and cellular debris.
iscussion
side from acute applications in cardiogenic shock (5–8), most
revious studies of long-term use of LVADs have been with
evices that completely replace the functioning of the heart.
he present study is the first to evaluate the long-term
emodynamic impact of partial ventricular support in patients
ith chronic heart failure. The estimated flow of the Synergy
ump in both the acute setting and during longer-term use was
3 l/min. The acute hemodynamic effects were similar to
hose observed previously with partial support devices (such as
he TandemHeart [CardiacAssist, Inc., Pittsburgh, Pennsyl-
ania] and Impella [Abiomed, Danvers, Massachusetts]
evices), with a 1.5 to 2 l/min increase in net cardiac
utput (i.e., the sum of flow through the device and native
ardiac output) and 7 mm Hg reduction in pulmonary
rtery diastolic pressure (a surrogate of pulmonary capillary
edge pressure), with relatively little impact on arterial
lood pressure (6,7).
These observations are also in complete alignment with
riginal theoretical predictions of the impact of 3 l/min
artial support in chronic heart failure (9). The important
ndings of the present study are that they confirm expec-
ations that under longer-term use, partial support would
ead to further improvements, which were evidenced by
ignificant further increases in arterial pressure and signifi-
ant reductions in pulmonary systolic pressures with main-
ained improvements in cardiac output and pulmonary
iastolic pressures. In the backdrop of this improved, stable,
nd more optimal hemodynamic profile, renal function was
aintained or even improved during the period of support.
The study targeted ambulatory patients on the transplant
aiting list with severe symptomatic heart failure but
reserved end-organ function who where not inotropic
ependent. Not uncommonly, this group of patients dete-
iorates over a relatively short period of time to the point at
hich they exhibit renal dysfunction, increasing fatigability,
nd dyspnea. Such patients are hospitalized more frequently
nd may require either inotropic support or a full-support
VAD. Examination of the baseline demographics and
emodynamics shows that the patients included in the
resent study were severely compromised and only slightly
etter than those enrolled in studies of full support assist
evices (11,12). For example, the clinical, hemodynamic
nd laboratory characteristics of the present cohort is not
hat different than that described for the recent HeartMate
I bridge-to-transplant study (12).
Two of the patients with more advanced disease
INTERMACS class 2 and 3) did not reach the treatment
oals of being free of inotropic support and out of the
ospital. These patients were accepted into the study after darlier successes and the hope that sicker patients (more
ypical of the normal LVAD population) could also benefit.
lthough treatment goals were not met, these patients were
onsidered clinical successes by the treating physicians
ecause the patients were successfully supported to trans-
lant without the need for implantation of a full support
evice.
The original version of the rotor used in the first 12
atients had a propensity for thrombus formation, resulting
n pump stoppages and the need for several pump ex-
hanges. Although this situation was problematic and re-
uired interruption of the study and relatively minor mod-
fication of the rotor, several important points were
emonstrated. First, the major advantages of having a
ubcutaneously placed pump were demonstrated; specifi-
ally, the pump could be changed without entering the
horax in a procedure that was as short as 30 min. Second,
f the patients are appropriately anticoagulated and the
ump is exchanged within a day of stoppage, the procedure
s relatively easy, and no embolic events were noted. How-
ver, if the device is allowed to thrombose extensively, there
s a significant risk of major thromboembolism during the
xchange procedure. Fortunately, after rotor modifications,
ump thrombosis has not been observed (9 implants with
urations of support almost reaching 4 months). Neverthe-
ess, it is reassuring to know that should a pump malfunc-
ion, an exchange procedure can be performed relatively
imply and that patients are adequately supported by their
ative cardiac output.
The present study represents the initial clinical experience
ith the Synergy system, with the longest duration of
upport being just 7 months. The main findings of
ustained improvements in patients’ hemodynamic profiles,
lthough very consistent, were obtained in a relatively small
umber of patients. Assessment of clinical benefits will
ltimately need to be made by comparing outcomes in
atients receiving the Synergy system versus those contin-
ed on medical therapy. Comparisons would include the
ature and severity of adverse events, the time spent in the
ospital and the ability to prevent heart failure deteriora-
ions as indexed by progressive end organ dysfunction, the
eed for long-term inotropic support, transplantation from
high urgency status, or insertion of a full-support ventric-
lar assist device.
The ultimate use of the Synergy system is as a permanent
mplant in patients who do not qualify for heart transplant,
ho have a very long expected wait time for a donor organ,
r in whom another sternotomy would be too difficult
ecause of previous cardiac operations. The results of the
resent study provide initial proof of concept that the heart
ailure state can be improved and stabilized by a device as
mall as Synergy pumping 3 l/min. The elective off-
ump implantation procedure performed through a mini-
horacotomy was well tolerated and not itself associated
ith any significant adverse events. Infections related to the
evice or driveline also were limited to one incidence that
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any of the patients returning home after relatively short
ospitalizations and resumption of physical therapy and
any activities, the present results provide important proof
f concept that a small, partial support pump implanted via
less invasive procedure can provide substantial clinical
enefits. Collectively, these findings set the stage for ex-
anding study of this device in longer-term applications,
ncluding nontransplant candidates.
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